Literature DB >> 25467081

Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.

Shruti Chaturvedi1, Erin Cockrell2, Ricardo Espinola3, Linda Hsi4, Stacey Fulton4, Mohammad Khan4, Liang Li5, Fabio Fonseca4, Suman Kundu4, Keith R McCrae6.   

Abstract

The antiphospholipid syndrome is characterized by venous or arterial thrombosis and/or recurrent fetal loss in the presence of circulating antiphospholipid antibodies. These antibodies cause activation of endothelial and other cell types leading to the release of microparticles with procoagulant and pro-inflammatory properties. The aims of this study were to characterize the levels of endothelial cell, monocyte or platelet derived, and tissue factor-bearing microparticles in patients with antiphospholipid antibodies, to determine the association of circulating microparticles with anticardiolipin and anti-β2-glycoprotein antibodies, and to define the cellular origin of microparticles that express tissue factor. Microparticle content within citrated blood from 47 patients with antiphospholipid antibodies and 144 healthy controls was analyzed within 2hours of venipuncture. Levels of Annexin-V, CD105 and CD144 (endothelial derived), CD41 (platelet derived) and tissue factor positive microparticles were significantly higher in patients than controls. Though levels of CD14 (monocyte-derived) microparticles in patient plasma were not significantly increased, increased levels of CD14 and tissue factor positive microparticles were observed in patients. Levels of microparticles that stained for CD105 and CD144 showed a positive correlation with IgG (R=0.60, p=0.006) and IgM anti-beta2-glycoprotein I antibodies (R=0.58, p=0.006). The elevation of endothelial and platelet derived microparticles in patients with antiphospholipid antibodies and their correlation with anti-β2-glycoprotein I antibodies suggests a chronic state of vascular cell activation in these individuals and an important role for β2-glycoprotein I in development of the pro-thrombotic state associated with antiphospholipid antibodies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiphospholipid; Endothelial cell; Microparticles; Platelet; Thrombosis

Mesh:

Substances:

Year:  2014        PMID: 25467081      PMCID: PMC4272916          DOI: 10.1016/j.thromres.2014.11.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  55 in total

1.  Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.

Authors:  K K Hamilton; R Hattori; C T Esmon; P J Sims
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

2.  Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells.

Authors:  N Del Papa; P L Meroni; A Tincani; E N Harris; S S Pierangeli; W Barcellini; M O Borghi; G Balestrieri; C Zanussi
Journal:  Clin Exp Rheumatol       Date:  1992 Jan-Feb       Impact factor: 4.473

3.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Koike
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

4.  Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.

Authors:  Carlos Perez-Sanchez; Nuria Barbarroja; Sebastiano Messineo; Patricia Ruiz-Limon; Antonio Rodriguez-Ariza; Yolanda Jimenez-Gomez; Munther A Khamashta; Eduardo Collantes-Estevez; M Jose Cuadrado; M Angeles Aguirre; Chary Lopez-Pedrera
Journal:  Ann Rheum Dis       Date:  2014-03-11       Impact factor: 19.103

5.  Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin.

Authors:  Mariano Vega-Ostertag; E Nigel Harris; Silvia S Pierangeli
Journal:  Arthritis Rheum       Date:  2004-09

6.  Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.

Authors:  E M Bevers; M Galli; T Barbui; P Comfurius; R F Zwaal
Journal:  Thromb Haemost       Date:  1991-12-02       Impact factor: 5.249

7.  E-Selectin mediates pathogenic effects of antiphospholipid antibodies.

Authors:  R G Espinola; X Liu; M Colden-Stanfield; J Hall; E N Harris; S S Pierangeli
Journal:  J Thromb Haemost       Date:  2003-04       Impact factor: 5.824

8.  Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies.

Authors:  K R McCrae; A DeMichele; P Samuels; D Roth; A Kuo; Q H Meng; J Rauch; D B Cines
Journal:  Br J Haematol       Date:  1991-12       Impact factor: 6.998

9.  Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus.

Authors:  A Vismara; P L Meroni; A Tincani; E N Harris; W Barcellini; A Brucato; M Khamashta; G R Hughes; C Zanussi; G Balestrieri
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

10.  Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome.

Authors:  Françoise Dignat-George; Laurence Camoin-Jau; Florence Sabatier; Dominique Arnoux; Francine Anfosso; Nathalie Bardin; Véronique Veit; Valéry Combes; Stéphanie Gentile; Valérie Moal; Marielle Sanmarco; José Sampol
Journal:  Thromb Haemost       Date:  2004-04       Impact factor: 5.249

View more
  15 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

3.  A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles.

Authors:  M Wu; J Barnard; S Kundu; K R McCrae
Journal:  J Thromb Haemost       Date:  2015-09-15       Impact factor: 5.824

4.  Platelet distribution width is highly associated with thrombotic events in primary antiphospholipid syndrome.

Authors:  Yu Shi; Hui Jiang; Can Huang; Chaojun Hu; Jiuliang Zhao; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2021-07-02       Impact factor: 2.980

Review 5.  Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges.

Authors:  Ula Štok; Saša Čučnik; Snežna Sodin-Šemrl; Polona Žigon
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 6.  Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis.

Authors:  Lina Badimon; Rosa Suades; Eduardo Fuentes; Iván Palomo; Teresa Padró
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

7.  Double-stranded DNA induces a prothrombotic phenotype in the vascular endothelium.

Authors:  Erik Gaitzsch; Thomas Czermak; Andrea Ribeiro; Yvonn Heun; Monica Bohmer; Monika Merkle; Hanna Mannell; Christian Schulz; Markus Wörnle; Joachim Pircher
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

8.  Circulating Microparticles Alter Formation, Structure, and Properties of Fibrin Clots.

Authors:  Laily D Zubairova; Roza M Nabiullina; Chandrasekaran Nagaswami; Yuriy F Zuev; Ilshat G Mustafin; Rustem I Litvinov; John W Weisel
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

Review 9. 

Authors:  Andreas Funke; Adriana Danowski; Danieli Castro Oliveira de Andrade; Jozelia Rêgo; Roger Abramino Levy
Journal:  J Vasc Bras       Date:  2017 Apr-Jun

Review 10.  Renal Involvement in Antiphospholipid Syndrome.

Authors:  Alonso Turrent-Carriles; Juan Pablo Herrera-Félix; Mary-Carmen Amigo
Journal:  Front Immunol       Date:  2018-05-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.